Estradiol — Endogenous estrogen / sex steroid hormone
17β-Estradiol (E2) is the primary endogenous estrogen in premenopausal women, produced predominantly by ovarian granulosa cells via aromatization of testosterone. Binds estrogen receptors (ERα and ERβ) — nuclear receptors that regulate transcription of hundreds of genes across uterus, breast, bone, cardiovascular system, brain, and liver. Genomic effects (hours to days): regulates FSHR, LHR, PR, and growth factor receptor expression. Non-genomic effects (minutes): rapid membrane-initiated signaling via mER. In menopause, loss of E2 causes: vasomotor symptoms (hot flashes via hypothalamic KNDy neuron disruption), urogenital atrophy (GSM), bone loss (increased osteoclast activity), mood instability, sleep disruption, and adverse cardiovascular remodeling. Transdermal routes bypass hepatic first-pass metabolism, eliminating hepatic protein synthesis stimulation (VTE risk significantly lower vs. oral).
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Endogenous estrogen / sex steroid hormone
آلية العمل
17β-Estradiol (E2) is the primary endogenous estrogen in premenopausal women, produced predominantly by ovarian granulosa cells via aromatization of testosterone. Binds estrogen receptors (ERα and ERβ) — nuclear receptors that regulate transcription of hundreds of genes across uterus, breast, bone, cardiovascular system, brain, and liver. Genomic effects (hours to days): regulates FSHR, LHR, PR, and growth factor receptor expression. Non-genomic effects (minutes): rapid membrane-initiated signaling via mER. In menopause, loss of E2 causes: vasomotor symptoms (hot flashes via hypothalamic KNDy neuron disruption), urogenital atrophy (GSM), bone loss (increased osteoclast activity), mood instability, sleep disruption, and adverse cardiovascular remodeling. Transdermal routes bypass hepatic first-pass metabolism, eliminating hepatic protein synthesis stimulation (VTE risk significantly lower vs. oral).
الوضع التنظيمي
FDA-approved for multiple indications: vasomotor symptoms, vulvar/vaginal atrophy, osteoporosis prevention, female hypogonadism, primary ovarian insufficiency.
مستوى الأدلة
Very High — WHI (n=16,608), ESTHER, E3N, SWAN cohort. NAMS 2022 position statement and IMS guidelines strongly support use within 10 years of menopause ('timing hypothesis').